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Abstract
Single site laparoscopy, while in its infancy, is being explored for potential areas 
of application within the realm of gynecology. Gynecologic Oncology is a field with 
high potential benefit from the single site technique. It boasts many practical and 
theoretical surgical improvements, such as facilitated specimen removal, which 
are elaborated further in this chapter. While much more research is needed, there 
are exciting and uniquely useful utilities of Laparo-endoscopic Single-site Surgery 
(LESS) in gynecology oncology.
Keywords: Gynecology Oncology, minimally invasive surgery, cancer,  
mini-laparotomy, surgical staging
1. Introduction
Historically, gynecologic oncology has been dominated by laparotomy for perito-
neal access, and this has carried partially even into the era of minimally invasive sur-
gery [1]. There were good reasons for initial concern regarding laparoscopy, including 
port site metastasis, intact specimen removal, and technical complications of staging. 
Many would credit the hallmark LAP2 trial [2] with forever changing the face of gyne-
cologic oncology, as it was the first high powered study to demonstrate laparoscopy 
to be comparable to laparotomy in gynecologic oncology procedures. This, combined 
with the already known advantages of minimally invasive surgery over classic lapa-
rotomy, launched the advent of laparoscopy in gynecologic oncology, in the opinion of 
many. The advantages were seen initially in the treatment of uterine cancer [3]. Many 
feel the extrapolation of this data was the impetus that eventually led to the saturation 
of minimally invasive surgery in the treatment of all other gynecologic malignant 
processes. With decreased length of stay, lower hernia rates, improved cosmesis, and 
lower infection rate, laparoscopy quickly became the preferred surgical methodology 
across gynecologic oncology. Gynecologic oncology has since contributed countless 
minimally invasive techniques since the LAP2 trial. Most notably, gynecologic oncolo-
gists were among the first to utilize and publish on single site laparoscopy [4–7].
Single site laparoscopic surgery provides many of the same potential improve-
ments in cosmesis as benign gynecology, but also may hold the critical benefit of 
facilitated intact specimen extraction [8]. Removal of the intact specimen is gener-
ally a critical aspect of oncologic surgery, as attempting to avoid tumor spillage into 
body cavities is a critical concept in the treatment of malignancy [9]. This fulfills 
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what many authors refer to as the so-called “Goldilocks” concept of specimen 
removal [10], allowing the surgical oncologist to laparoscopically remove larger 
organ systems, a feat which which would have required laparotomy previously. 
Multiple methods of large specimen extraction in standard laparoscopy have been 
described, ranging from mini-laparotomy [11, 12] and nonstandard incisions [13], 
to incisional extension. While useful techniques, these are less studied in malignant 
processes and their long term sequelae are less elucidated. Therein, many would 
consider that Laparoendoscopic Single-site Surgery (LESS) techniques have great 
merit and promise in Gynecologic Oncology (Figure 1).
2. Applications for gynecologic oncology
The majority of studies done to date in gynecology oncologic are case series or 
longitudinal studies done at major facilities in the United States, United Kingdom, 
and China. The first reports of use and feasibility highlighted the expected benefits 
of standard laparoscopy with the improvement of single incision cosmesis, decreased 
blood loss, and decreased pain. Decreased pain was the most consistent finding 
among early publications, which was noted in a Cochrane review of LESS in benign 
and oncologic gynecology [14]. Here we will outline specific advantages of the single-
site technique and other considerations for specific gynecologic malignant processes.
2.1 Uterine cancers
The majority of LESS procedures have been performed for hysterectomy in 
uterine cancers, (mirroring the LAP2 trial [2]) and for risk-reducing salpingecto-
mies. These have included, in some studies, lymphadenectomy for cancer staging 
purposes [15]. Given the literature available, there are many potential benefits 
Figure 1. 
(A) Completion of Salpingectomy vNTOES single site (B) Single site vNOTES visualization of the ureter. 
(C) Large adnexal mass liberated during laparoscopic single site surgery. (D) Uterine artery ligation and 
cauterization during vNOTES.
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offered by LESS techniques, including: preventing peritoneal tumor spillage, tissue 
preservation for pathologic analysis, and facilitation of extraction.
LESS requires more time to master for advanced retroperitoneal dissection and 
lymphadenectomies, but a surgeon adept at traditional laparoscopic surgery can 
overcome these challenges and master these techniques relatively quickly. Patient 
selection is also of the utmost importance, as obesity is a well known major risk 
factor for endometrial cancer, and this excess adiposity can increase the difficulty 
of the already complex LESS procedure.
In 2012 a publication from Memorial Sloan Kettering Cancer Center on sentinel 
node biopsy in endometrial cancer, it was suggested to change the standard practice 
in the United States to a sentinel node algorithm rather than comprehensive lymph-
adenectomy in most patients with endometrial adenocarcinoma [16]. Their algo-
rithm suggested: (1) peritoneal evaluation thorough inspection and washing, (2) 
retroperitoneal evaluation with excision of all mapped or suspicious nodes, (3) side 
specific lymph node dissection in case of no mapping into a hemi-pelvis, (4) para-
aortic node dissection performed at the discretion of the attending surgeon [12].
Sentinel node biopsy and mapping was gained acceptance as the standard of 
care for endometrial cancer. This comes after multiple publications such as the 
FIRES trial which paved the way for the NCCN guidelines suggesting LESS tech-
niques may be adopted more easily, given the need for less extensive dissection and 
ease at transition to a multiport procedure when needed [17].
A new subfield of LESS, vaginal natural orifice transluminal endoscopic surgery 
(vNOTES) is emerging in the field of gynecologic surgery. While the vast majority 
of investigation of vNOTES has been in benign gynecology, there are recent docu-
mented applications for oncologic purposes, specifically for early stage endometrial 
cancer (Figure 2).
Figure 2. 
Single site wound retractor applied to the vagina status post vaginal hysterectomy, accessing the peritoneum for 
vNOTES procedure.
Single Port Gynecologic Laparoscopic and Robotic - Assisted Surgery
4
2.2 Cervical cancers
Interestingly, there were successful publications on using single-site for radical 
hysterectomy for early stage cervical cancers. The theoretical benefits of LESS were 
similar to the general benefits mentioned previously. Unfortunately, a landmark 
2018 study performed by Ramirez et al., (the LACC trial,) [18] demonstrated a 
decrease in overall and disease-free survival with laparoscopic radical hysterecto-
mies for early cervical cancers. As a result, laparoscopic radical hysterectomies have 
become rare in practice [19]. Therefore, until confounding literature published, 
many gynecologic oncologists feel the utility of LESS for radical hysterectomy is 
limited and maybe more of an interesting historical footnote than a viable procedure.
2.3 Ovarian cancer
While it is widely considered that advanced ovarian cancers may still be best 
managed via laparotomy, laparoscopy and robot assisted laparoscopy is still rou-
tinely utilized in early stage ovarian cancers. Complete staging is imperative for 
all ovarian malignancies. The protocol for assessing these early ovarian cancers 
includes: lymph node dissection, peritoneal biopsies, and omentectomy. These mea-
sures allow for peritoneal sampling which allows for improved detection of micro-
metastatic disease, which, in turn, optimizes adjuvant chemotherapeutic selection 
and prognosis for patients.
Perhaps the greatest area of potential use in Gynecologic Oncology for LESS 
techniques would be adnexal masses. When the uterus is left in situ in traditional 
laparoscopic surgery retrieval of a large adnexal mass can be very frustrating. A 10 
or 12 mm incision is often not large enough for removal of a large specimen. As a 
result, this scenario requires an incision to be extended, (including fascial exten-
sion) and creates a risk of injury to the bowel or other structures, as well as a risk 
of spillage from the isolating bag. LESS techniques in general will require a 2-3 cm 
umbilical incision but this can be made larger for certain clinical scenarios. Making 
the incision in a natural defect such as the umbilicus can yield excellent cosmetic 
results when a larger incision for extraction is required [20].
For a suspicious mass large extraction bags are available in sizes up to 17 cm. 
These vary in size and shape and are available from various manufacturers. They 
can be deployed intraperitoneally and the mass can be brought out through the 
umbilical incision, or if necessary, drained while contained. If a frozen section 
Figure 3. 
Omentectomy at the time of minimally invasive removal of suspicious ovarian cyst.
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is obtained and this reveals a borderline or ovarian malignancy, the surgeon may 
feel an infracolic omentectomy is indicated. Generally, the LESS port provides 
an incision large enough to deliver omentum intact and large enough to perform 
a relatively easy and quick infracolic omentectomy using whatever laparoscopic 
energy device has already been used. This technique is similar to previous described 
techniques of omentectomy performed through a miniature laparotomy (Figure 3).
For the very large benign appearing mass with normal tumor markers in a young 
patient, a LESS approach through the umbilicus can facilitate contained drainage. 
After placing the LESS port of choice the mass can be visualized before insufflation. 
One technique is to place two purse string sutures of 3-0 monofilament suture into 
the mass concentric to each other. A small hole is then made and the suction aspira-
tor inserted with the inner stitch tied to contain leakage. Once the mass is decom-
pressed the suction aspirator is removed, and the outer stitch can be tied to prevent 
any further spillage. The decompressed mass is then removed laparoscopically. The 
slightly large incision in the umbilicus usually allows for easy removal.
It is important to note that the above techniques for adnexal mass removal are 
not appropriate for all patients. For any patients in which a malignancy is suspected, 
great care must be taken to avoid any technique that introduces the risk of spilling 
malignant cells in the abdominal cavity, effectively working to spread the lesion. For 
patients with a low suspicion of malignancy, however, we feel that the technique is a 
welcome addition to the armamentarium of the gynecologic surgeon. We welcome 
further research, including case studies and described techniques. This will serve 
to further develop the minimally invasive literature as well as to stimulate ideas for 
new clinical trial protocols.
2.4 Robotic applications
A number of studies have been performed in the realm of benign gynecology 
with robotic LESS with varied success. Few, however, have been published specifi-
cally on oncologic robotic surgery. The most notable of these demonstrated the 
feasibility of robotic single-site [21]. The benefits and pitfalls of robotic single-site 
surgery are similar to benign gynecology as previously discussed in this text [22].
3. Limitations and considerations
Despite the various sources listed in this chapter and the multitude of studies 
on LESS for gynecologic oncology, there is an overall lack of data on the topic 
given its relatively new emergence. With only a decade passing since first recorded 
data in this topic, more research will need done before long-term conclusions can 
be drawn. To date, the longest single study follow up our authors could find was 
3 years [23, 24].
Perhaps more than any other adverse outcome, there is evidence that LESS tech-
niques may hold a higher hernia rate than previously expected [1, 13–16]. One study 
by Multon et al. demonstrated that hernia rates within 1 year are similar to standard 
laparoscopy (5.5%), 3 year follow up seemed to indicate a significant increase in 
hernia rates as high as 23% [1]. As a result, several authors have stated that it would 
appear the increased incision size for LESS may have a greater effect on incisional 
hernia than previously thought [25, 26].
The technical difficulties of LESS techniques are identical to the benign gyne-
cologic applications of the surgical method, including loss of triangulation, arm 
clashing, and surgeon comfort [27]. With training, time, and improving surgical 
instruments, these limitations may be overcome.
Single Port Gynecologic Laparoscopic and Robotic - Assisted Surgery
6
Author details
Conor J. Corcoran1 and Stephen H. Bush II 1,2*
1 Charleston Area Medical Center, USA
2 West Virginia University School of Medicine Charleston Division, USA
*Address all correspondence to: sbush1@gmail.com
4. Conclusion
LESS appears to be a viable, safe alternative to standard laparoscopy for most 
gynecologic oncology procedures. While more research is needed and is ongoing, it 
is the hope of the authors that more will endeavor and utilize single-site techniques 
for oncologic cases.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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